Skip to main content

Advertisement

SpringerLink
Log in

Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Although the critical role of complement component C3d as a molecular adjuvant in preventing virus infection is well established, its role in cancer prophylaxis and treatment is unclear. In this study, we constructed a recombinant plasmid encoding Flk-1 and C3d3 fusion proteins and investigated its transient expression in vitro in transfected eukaryotic cells and its antibody response in immunized mice. Subsequently, we investigated the vaccine’s ability to elicit an immune response leading to suppression of angiogenesis and tumor growth in mice bearing bladder transitional cell carcinoma. Using Western blotting, immunocytochemistry, and flow cytometry, we detected the expression of Flk-1 and C3d3 fusion proteins in COS-7 cells transfected with these recombinant plasmids. Further binding experiment using CR2 (C3d receptor) positive Raji cells that were incubated with transfected COS-7 supernatant indicated that C3d was successfully fused to Flk-1. Although both vaccines elicited peak antibody levels at 5 weeks, Flk-1-specific antibody titer in pSG.SS.Flk-1ECD.C3d3.YL-immunized mice was significantly higher when compared to pSG.SS.Flk-1ECD.YL-immunized mice. The results of experiments with bladder tumor-bearing mice showed that the vaccine inhibited tumor growth significantly. These results suggest that C3d plays a critical role in tumor immunotherapy by promoting antibody response in Flk-1-based DNA vaccines. This approach may provide a new strategy for the rational design of anti-angiogenic therapies for the treatment of solid tumors and provide a basis for the further exploitation and application of the anti-angiogenesis DNA vaccines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Folkman J (1971) Tumor angiogenesis: therapeutic implication. N Engl J Med 285:1182–1186

    PubMed  CAS  Google Scholar 

  2. Bhat TA, Singh RP (2008) Tumor angiogenesis-A potential target in cancer chemoprevention. Food Chem Toxicol 46:1334–1345

    Article  PubMed  CAS  Google Scholar 

  3. Bamias A, Dimopoulos MA (2003) Angiogenesis in human cancer: implications in cancer therapy. Eur J Intern Med 14:459–469

    Article  PubMed  CAS  Google Scholar 

  4. Koehl GE, Wagner F, Stoeltzing O et al (2007) Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation 83:607–614

    Article  PubMed  CAS  Google Scholar 

  5. Niethammer AG, Xiang R, Becker JC et al (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8:1369–1375

    Article  PubMed  CAS  Google Scholar 

  6. Rad FH, Le Buanec H, Paturance S et al (2007) VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 104:2837–2842

    Article  PubMed  CAS  Google Scholar 

  7. Reisfeld RA, Niethammer AG, Luo Y et al (2004) DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis. Int Arch Allergy Immunol 133:295–304

    Article  PubMed  CAS  Google Scholar 

  8. Liu JY, Wei YQ, Yang L et al (2003) Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102:1815–1823

    Article  PubMed  CAS  Google Scholar 

  9. Boehm T, Folkman J, Browder T et al (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404–407

    Article  PubMed  CAS  Google Scholar 

  10. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795–803

    Article  PubMed  CAS  Google Scholar 

  11. Hou JM, Liu JY, Yang L et al (2005) Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Oncology 69:81–87

    Article  PubMed  CAS  Google Scholar 

  12. Alessi P, Ebbinghaus C, Neri D (2004) Molecular targeting of angiogenesis. Biochim Biophys Acta 1654:39–49

    PubMed  CAS  Google Scholar 

  13. Abdollahi A, Lipson KE, Han X et al (2003) SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63:3755–3763

    PubMed  CAS  Google Scholar 

  14. Singhal S, Vachani A, Antin-Ozerkis D et al (2005) Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11:3974–3986

    Article  PubMed  CAS  Google Scholar 

  15. Dempsey PW, Allison ME, Akkaraju S et al (1996) C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348–350

    Article  PubMed  CAS  Google Scholar 

  16. Wang L, Sunyer JO, Bello LJ (2004) Fusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus. J Virol 78:1616–1622

    Article  PubMed  CAS  Google Scholar 

  17. Fan H, Tong T, Chen H et al (2007) Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus. Virus Genes 35:347–357

    Article  PubMed  CAS  Google Scholar 

  18. Green TD, Newton BR, Rota PA et al (2001) C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 20:242–248

    Article  PubMed  CAS  Google Scholar 

  19. Hannan JP, Young KA, Guthridge JM et al (2005) Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d. J Mol Biol 346(3):845–858

    Article  PubMed  CAS  Google Scholar 

  20. Hess MW, Schwendinger MG, Eskelinen EL et al (2000) Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21). Blood 95:2617–2623

    PubMed  CAS  Google Scholar 

  21. Cherukuri A, Cheng PC, Pierce SK (2001) The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J Immunol 167:163–167

    PubMed  CAS  Google Scholar 

  22. Konozo Y, Abe R, Konozo H et al (1998) Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cell. J Immunol 160:1565–1572

    Google Scholar 

  23. Bower JF, Ross TM (2006) A minimum CR2 binding domain of C3d enhances immunity following vaccination. Adv Exp Med Biol 586:249–264

    Article  PubMed  CAS  Google Scholar 

  24. Jegou JF, Chan P, Schouft MT et al (2007) C3d binding to the myelin oligodendrocyte glycoprotein results in an exacerbated experimental autoimmune encephalomyelitis. J Immunol 178:3323–3331

    PubMed  CAS  Google Scholar 

  25. Knopf PM, Rivera DS, Hai SH et al (2008) Novel function of complement C3d as an autologous helper T-cell target. Immunol Cell Biol 86:221–225

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to thank the study participants for their cooperation, which made this study possible. They are also grateful to the National Natural Science Foundation of China for its financial support (No. 30571864).

Conflict of interest statement

The authors have no financial conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Daping Hospital, The Third Military Medical University, 10 Changjiang Branch Road, Yuzhong District, 400042, Chongqing, China

    Pei-he Liang, Ke-qin Zhang, Yan-feng Li, Luo-fu Wang, Zhi-lin Nie, Jin Ye, Gang Wu, Cheng-guo Ge & Feng-shuo Jin

  2. Research Institute of Immunology, The Third Military Medical University, Chongqing, China

    Gui-lian Xu

Authors
  1. Pei-he Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ke-qin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gui-lian Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan-feng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luo-fu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhi-lin Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jin Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Cheng-guo Ge
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Feng-shuo Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Feng-shuo Jin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liang, Ph., Zhang, Kq., Xu, Gl. et al. Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth. Cancer Immunol Immunother 59, 93–101 (2010). https://doi.org/10.1007/s00262-009-0727-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-009-0727-2

Keywords

Search

Navigation